Lv3
238 积分 2026-02-26 加入
An immunoinhibition approach to overcome the impact of pre-existing antibodies on cut point establishment for immunogenicity assessment of moxetumomab pasudotox
8天前
已完结
A novel approach to assess domain specificity of anti-drug antibodies to moxetumomab pasudotox, an immunotoxin with two functional domains
10天前
已完结
Soluble Programmed Cell Death Ligand 1 as a Novel Biomarker for Nivolumab Therapy for Non–Small-cell Lung Cancer
21天前
已完结
Development of Therapeutic Proteins for a New Subcutaneous Route of Administration After the Establishment of Intravenous Dosages: A Systematic Review
1个月前
已完结
Switching to daratumumab SC from IV is safe and preferred by patients with multiple myeloma
1个月前
已完结
Subcutaneous versus intravenous daratumumab in patients with relapsed or refractory multiple myeloma (COLUMBA): a multicentre, open-label, non-inferiority, randomised, phase 3 trial
1个月前
已完结
Target Occupancy Biomarker Assay Development Using a Conformation-Selective Antibody Against Small-Molecule-Bound TNF
2个月前
已完结
Estimation of the serum level of a proliferation-inducing ligand in patients with psoriasis and lichen planus
3个月前
已关闭
A Phase 3 Trial of Telitacicept for Systemic Lupus Erythematosus
4个月前
已完结
皖公网安备34019202002308
